BOOM
Recent additions may not be included but will usually appear in 24 hrs or less.
| Rational | Source |
|---|---|
|
Comparison of the Effects of Essential Oils from Cannabis sativa and Cannabis indica on Selected Bacteria, Rumen Fermentation, and Methane Production-In Vitro Study. ✅
Go to Publication ✅
International journal of molecular sciences (Int J Mol Sci ) Vol: 25 Issue 11 Pages: Pub: 2024 May 28 Epub: 2024 May 28 Authors Tabis A , Szumny A , Bania J , Pacyga K , Lewandowska K , Kupczynski R , |
|
|
Combination of cannabinoids, delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), mitigates experimental autoimmune encephalomyelitis (EAE) by altering the gut microbiome. ✅
Go to Publication ✅
Brain, behavior, and immunity (Brain Behav Immun ) Vol: 82 Issue Pages: 25-35 Pub: 2019 Nov Epub: 2019 Jul 26 Authors Al-Ghezi ZZ , Busbee PB , Alghetaa H , Nagarkatti PS , Nagarkatti M , |
|
|
Integrating fecal metabolomics and intestinal microbiota to study the mechanism of cannabidiol in the treatment of idiopathic pulmonary fibrosis. ✅
Go to Publication ✅
Frontiers in pharmacology (Front Pharmacol ) Vol: 15 Issue Pages: 1358626 Pub: 2024 Epub: 2024 Feb 6 Authors Sun M , Zhang F , Lu F , Yu D , Wang Y , Chen P , Liu S , |
|
|
Integrating fecal metabolomics and intestinal microbiota to study the mechanism of cannabidiol in the treatment of idiopathic pulmonary fibrosis. ✅
Go to Publication ✅
Frontiers in pharmacology (Front Pharmacol ) Vol: 15 Issue Pages: 1358626 Pub: 2024 Epub: 2024 Feb 6 Authors Sun M , Zhang F , Lu F , Yu D , Wang Y , Chen P , Liu S , |
|
|
Integrating fecal metabolomics and intestinal microbiota to study the mechanism of cannabidiol in the treatment of idiopathic pulmonary fibrosis. ✅
Go to Publication ✅
Frontiers in pharmacology (Front Pharmacol ) Vol: 15 Issue Pages: 1358626 Pub: 2024 Epub: 2024 Feb 6 Authors Sun M , Zhang F , Lu F , Yu D , Wang Y , Chen P , Liu S , |
|
|
Integrating fecal metabolomics and intestinal microbiota to study the mechanism of cannabidiol in the treatment of idiopathic pulmonary fibrosis. ✅
Go to Publication ✅
Frontiers in pharmacology (Front Pharmacol ) Vol: 15 Issue Pages: 1358626 Pub: 2024 Epub: 2024 Feb 6 Authors Sun M , Zhang F , Lu F , Yu D , Wang Y , Chen P , Liu S , |
|
|
Integrating fecal metabolomics and intestinal microbiota to study the mechanism of cannabidiol in the treatment of idiopathic pulmonary fibrosis. ✅
Go to Publication ✅
Frontiers in pharmacology (Front Pharmacol ) Vol: 15 Issue Pages: 1358626 Pub: 2024 Epub: 2024 Feb 6 Authors Sun M , Zhang F , Lu F , Yu D , Wang Y , Chen P , Liu S , |
|
|
Integrating fecal metabolomics and intestinal microbiota to study the mechanism of cannabidiol in the treatment of idiopathic pulmonary fibrosis. ✅
Go to Publication ✅
Frontiers in pharmacology (Front Pharmacol ) Vol: 15 Issue Pages: 1358626 Pub: 2024 Epub: 2024 Feb 6 Authors Sun M , Zhang F , Lu F , Yu D , Wang Y , Chen P , Liu S , |
|
|
Integrating fecal metabolomics and intestinal microbiota to study the mechanism of cannabidiol in the treatment of idiopathic pulmonary fibrosis. ✅
Go to Publication ✅
Frontiers in pharmacology (Front Pharmacol ) Vol: 15 Issue Pages: 1358626 Pub: 2024 Epub: 2024 Feb 6 Authors Sun M , Zhang F , Lu F , Yu D , Wang Y , Chen P , Liu S , |
|
|
Integrating fecal metabolomics and intestinal microbiota to study the mechanism of cannabidiol in the treatment of idiopathic pulmonary fibrosis. ✅
Go to Publication ✅
Frontiers in pharmacology (Front Pharmacol ) Vol: 15 Issue Pages: 1358626 Pub: 2024 Epub: 2024 Feb 6 Authors Sun M , Zhang F , Lu F , Yu D , Wang Y , Chen P , Liu S , |
|
|
The impact of medical cannabis consumption on the oral flora and saliva. ✅
Go to Publication ✅
PloS one (PLoS One ) Vol: 16 Issue 2 Pages: e0247044 Pub: 2021 Epub: 2021 Feb 12 Authors Habib G , Steinberg D , Jabbour A , |
|
|
Comparative Analysis of the Antimicrobial Activity of Essential Oils and Their Formulated Microemulsions against Foodborne Pathogens and Spoilage Bacteria. ✅
Go to Publication ✅
Antibiotics (Basel, Switzerland) (Antibiotics (Basel) ) Vol: 11 Issue 4 Pages: Pub: 2022 Mar 25 Epub: 2022 Mar 25 Authors Campana R , Tiboni M , Maggi F , Cappellacci L , Cianfaglione K , Morshedloo MR , Frangipani E , Casettari L , |
|
|
Phytochemical characterization and biological properties of two standardized extracts from a non-psychotropic Cannabis sativa L. cannabidiol (CBD)-chemotype. ✅
Go to Publication ✅
Phytotherapy research : PTR (Phytother Res ) Vol: 35 Issue 9 Pages: 5269-5281 Pub: 2021 Sep Epub: 2021 Jun 26 Authors Muscarà C , Smeriglio A , Trombetta D , Mandalari G , La Camera E , Grassi G , Circosta C , |
|
|
Cannabinoids from inflorescences fractions of Trema orientalis (L.) Blume (Cannabaceae) against human pathogenic bacteria. ✅
Go to Publication ✅
PeerJ (PeerJ ) Vol: 9 Issue Pages: e11446 Pub: 2021 Epub: 2021 May 13 Authors Napiroon T , Tanruean K , Poolprasert P , Bacher M , Balslev H , Poopath M , Santimaleeworagun W , |
|
|
Cannabinoids-Promising Antimicrobial Drugs orIntoxicants with Benefits? ✅
Go to Publication ✅
Antibiotics (Basel, Switzerland) (Antibiotics (Basel) ) Vol: 9 Issue 6 Pages: Pub: 2020 Jun 2 Epub: 2020 Jun 2 Authors Klahn P , |
|
|
Antibacterial cannabinoids from Cannabis sativa: a structure-activity study. ✅
Go to Publication ✅
Journal of natural products (J Nat Prod ) Vol: 71 Issue 8 Pages: 1427-30 Pub: 2008 Aug Epub: 2008 Aug 6 Authors Appendino G , Gibbons S , Giana A , Pagani A , Grassi G , Stavri M , Smith E , Rahman MM , |
|
|
Formulation, Characterization and Properties of Hemp Seed Oil and Its Emulsions. ✅
Go to Publication ✅
Molecules (Basel, Switzerland) (Molecules ) Vol: 22 Issue 5 Pages: Pub: 2017 Apr 27 Epub: 2017 Apr 27 Authors Mikulcová V , Kašpárková V , Humpolícek P , Bunková L , |
|
|
The antimicrobial potential of cannabidiol. ✅
Go to Publication ✅
Communications biology (Commun Biol ) Vol: 4 Issue 1 Pages: 7 Pub: 2021 Jan 19 Epub: 2021 Jan 19 Authors Blaskovich MAT , Kavanagh AM , Elliott AG , Zhang B , Ramu S , Amado M , Lowe GJ , Hinton AO , Pham DMT , Zuegg J , Beare N , Quach D , Sharp MD , Pogliano J , Rogers AP , Lyras D , Tan L , West NP , Crawford DW , Peterson ML , Callahan M , Thurn M , |
|
|
The antimicrobial potential of cannabidiol. ✅
Go to Publication ✅
Communications biology (Commun Biol ) Vol: 4 Issue 1 Pages: 7 Pub: 2021 Jan 19 Epub: 2021 Jan 19 Authors Blaskovich MAT , Kavanagh AM , Elliott AG , Zhang B , Ramu S , Amado M , Lowe GJ , Hinton AO , Pham DMT , Zuegg J , Beare N , Quach D , Sharp MD , Pogliano J , Rogers AP , Lyras D , Tan L , West NP , Crawford DW , Peterson ML , Callahan M , Thurn M , |
|
|
The antimicrobial potential of cannabidiol. ✅
Go to Publication ✅
Communications biology (Commun Biol ) Vol: 4 Issue 1 Pages: 7 Pub: 2021 Jan 19 Epub: 2021 Jan 19 Authors Blaskovich MAT , Kavanagh AM , Elliott AG , Zhang B , Ramu S , Amado M , Lowe GJ , Hinton AO , Pham DMT , Zuegg J , Beare N , Quach D , Sharp MD , Pogliano J , Rogers AP , Lyras D , Tan L , West NP , Crawford DW , Peterson ML , Callahan M , Thurn M , |
BOOM
All suggestions are computed solely on their predicted microbiome impact. Safety, side-effects etc must be evaluated by your medical professionals before starting. Some items suggests have significant risk of adverse consequences for some people.
Special thanks to David F Morrison and Geert Van Houcke for doing Quality Assurance. Special thanks to Oliver Luk, B.Sc. (Biology) from BiomeSight for spot checking the coding of data from the US National Library of Medicine
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Copyright 2016-2023 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.
